Physician profile
William Herrera
NPI 1730181645
$6,709.32
in general payments reported to CMS, 2019-2025
36 companies · $201 in 2025
The $201 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $949 · 2020: $752 · 2021: $679 · 2022: $1,356 · 2023: $1,634 · 2024: $1,138 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,973.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,972.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,204.15 | 2021-2025 | |
| Ucb, INC. | $1,032.42 | 2019-2025 | Briviact |
| Teva Pharmaceuticals USA, INC. | $639.19 | 2019-2024 | Austedo Xr, Austedo, Ajovy |
| Neurelis, INC. | $449.94 | 2020-2024 | Valtoco |
| Novartis Pharmaceuticals Corporation | $413.53 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $364.94 | 2020-2024 | Ultomiris, Soliris |
| Biogen, INC. | $250.90 | 2019-2023 | Vumerity, Tysabri |
| Pfizer INC. | $239.36 | 2023-2025 | |
| Supernus Pharmaceuticals, INC. | $186.69 | 2019-2021 | |
| Allergan, INC. | $167.66 | 2019-2020 | |
| Amgen INC. | $166.69 | 2019-2023 | Aimovig |
| Horizon Therapeutics Plc | $129.45 | 2021-2023 | Uplizna |
| Neurocrine Biosciences, INC. | $124.00 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $119.70 | 2019-2022 | |
| Celgene Corporation | $117.64 | 2022-2024 | Zeposia |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $110.48 | 2022-2023 | |
| Argenx US, INC. | $108.85 | 2022-2024 | Vyvgart Hytrulo, Vyvgart |
| Emd Serono, INC. | $103.65 | 2020-2022 | |
| Acadia Pharmaceuticals INC | $93.93 | 2019-2020 | |
| Lundbeck LLC | $85.20 | 2023-2025 | Vyepti |
| Jazz Pharmaceuticals INC. | $76.41 | 2022-2023 | Epidiolex |
| Biohaven Pharmaceutical Holding Company Ltd. | $57.99 | 2022 | |
| Tg Therapeutics, INC. | $48.57 | 2024 | |
| Csl Behring | $45.83 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $45.37 | 2020-2021 | |
| Livanova USA, INC. | $45.07 | 2019 | |
| Eisai INC. | $43.66 | 2022 | |
| Upsher-Smith Laboratories LLC | $41.83 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $38.05 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.31 | 2024 | Hyqvia |
| Tanabe Pharma America, INC. | $26.43 | 2022 | |
| Sk Life Science, INC. | $26.16 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $19.45 | 2019 | |
| Kyowa Kirin, INC. | $18.25 | 2022 | |
| Alnylam Pharmaceuticals INC. | $17.93 | 2021 | |
| Acorda Therapeutics, INC | $17.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Herrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.